A Simple Neuroprotection Trial in Parkinson's Disease

帕金森病的简单神经保护试验

• 批准号: 7694987
• 负责人: LISA M. SHULMAN
• 金额: $ 5.01万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-30 至 2012-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7694987
• 关键词: Clinical; Clinical Treatment; Clinical Trials; Communities; Disease Progression; Double-Blind Method; Enrollment; Maryland; Methods; Movement Disorders; Neurodegenerative Disorders; Neurologist; Nursing Homes; Occupations; Outcome; Parkinson Disease; Patients; Randomized; Research Personnel; Sampling; Site; Toxic effect; Universities; design; disability; experience; follow-up; innovation; medical schools; neuroprotection; treatment effect

DESCRIPTION (provided by applicant): Parkinson's disease is a progressive neurodegenerative disorder which often results in disability. If pharmacological agents could slow the progression of disease early disability, job loss, and nursing home placement might be delayed. This clinical trial utilizing a randomized, double blind design will evaluate the efficacy of one or more pharmacological agents for slowing progression of Parkinson's disease and will determine the toxicity and tolerability of these agents. The trial will enroll patients with Parkinson's disease who recently started dopaminergic therapy, will be able to detect small treatment effects, will incorporate innovative sample follow-up methods, and will be able to distinguish neuroprotective effects from occult symptomatic benefits. This center will be one of 42 clinical centers designated to participate in this study.

描述（由申请人提供）：帕金森氏病是一种进行性神经退行性疾病，通常导致残疾。如果药理学药物可以减慢早期残疾的进展，就可以延迟失业和疗养院的安置。这项利用随机，双盲设计的临床试验将评估一种或多种药理学剂减缓帕金森氏病进展的功效，并确定这些药物的毒性和耐受性。该试验将招募帕金森氏病的患者，这些患者最近开始开始多巴胺能疗法，能够检测到小型治疗效果，将纳入创新的样本随访方法，并能够将神经保护作用与神秘的症状益处区分开。该中心将是指定参与这项研究的42个临床中心之一。